Sustained-release fluocinolone acetonide intravitreal insert for macular edema: clinical pharmacology and safety evaluation

Bibliography

• Ossewaarde-van Norel A, Rothova A. Clinical review: update on treatment of inflammatory macular edema. Ocul Immunol Inflamm 2011;19:75–83
   PubMed Web of Science ®Google Scholar
• Shamsi HN, Masaud JS, Ghazi NG. Diabetic macular edema: New promising therapies. World J Diabetes 2013;4:324-38
   Google Scholar
• Gulati N, Forooghian F, Lieberman R, et al. Vascular endothelial growth factor inhibition in uveitis: a systematic review. Br J Ophthalmol 2011;95:162-5
   PubMed Web of Science ®Google Scholar
• Glanville J, Patterson J, McCool R, et al. Efficacy and safety of widely used treatments for macular oedema secondary to retinal vein occlusion: a systematic review. BMC Ophthalmol 2014;14:7
   PubMed Web of Science ®Google Scholar
• Scholl S, Augustin A, Loewenstein A, et al. General pathophysiology of macular edema. Eur J Ophthalmol 2011;21(Suppl 6):S10-19
   PubMed Web of Science ®Google Scholar
• Smiddy WE. Economic considerations of macular edema therapies. Ophthalmology 2011;118:1827-33
   PubMed Web of Science ®Google Scholar
• van der Velden VH. Glucocorticoids: mechanisms of action and anti-inflammatory potential in asthma. Mediators Inflamm 1998;7:229-37
   PubMed Web of Science ®Google Scholar
• Cabrera M, Yeh S, Albini TA. Sustained-release corticosteroid options. J Ophthalmol 2014:164692
   Google Scholar
• Cutino A, Green K, Kendall R, et al. Economic evaluation of a fluocinolone acetonide intravitreal implant for patients with DME based on the FAME study. Am J Manag Care 2015;21(4 Suppl):s63-72
   PubMed Web of Science ®Google Scholar
• Iluvien® - highlights of prescribing information 2014. Available from: www.alimerasciences.com/wp-content/uploads/2014/09/iluvien-prescribing-information.pdf [Last accessed 10 December 2014]
   Google Scholar
• Arcinue CA, Ceron OM, Foster CS. A comparison between the fluocinolone acetonide (Retisert) and dexamethasone (Ozurdex) intravitreal implants in uveitis. J Ocul Pharmacol Ther 2013;29:501-7
   PubMed Web of Science ®Google Scholar
• Jaffe GJ, Yang CH, Guo H, et al. Safety and pharmacokinetics of an intraocular fluocinolone acetonide sustained delivery device. Invest Ophthalmol Vis Sci 2000;41:3569-75
   PubMed Web of Science ®Google Scholar
• pSivida Corp. Products (iluvien). Diabetic macular edema. Available from: http://www.psivida.com/products-iluvien.html [Last accessed 26 January 2015]
   Google Scholar
• Jaffe GJ, Martin D, Callanan D, et al. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology 2006;113:1020-7
   PubMed Web of Science ®Google Scholar
• Callanan DG, Jaffe GJ, Martin DF, et al. Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results. Arch Ophthalmol 2008;126:1191-201
   PubMed Web of Science ®Google Scholar
• Pavesio C, Zierhut M, Bairi K, et al. Evaluation of an intravitreal fluocinolone acetonide implant versus standard systemic therapy in noninfectious posterior uveitis. Ophthalmology 2010;117:567-75; 75 e1
   PubMed Web of Science ®Google Scholar
• Fluocinolone acetonide ophthalmic-Bausch & Lomb: fluocinolone acetonide Envision TD implant. Drugs R D 2005;6:116-19
   PubMedGoogle Scholar
• Pearson PA, Comstock TL, Ip M, et al. Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3-year multicenter, randomized, controlled clinical trial. Ophthalmology 2011;118:1580-7
   PubMed Web of Science ®Google Scholar
• Kane FE, Burdan J, Cutino A, et al. Iluvien: a new sustained delivery technology for posterior eye disease. Expert Opin Drug Deliv 2008;5:1039-46
   PubMed Web of Science ®Google Scholar
• Campochiaro PA, Nguyen QD, Hafiz G, et al. Aqueous levels of fluocinolone acetonide after administration of fluocinolone acetonide inserts or fluocinolone acetonide implants. Ophthalmology 2013;120:583-7
   PubMed Web of Science ®Google Scholar
• Driot JY, Novack GD, Rittenhouse KD, et al. Ocular pharmacokinetics of fluocinolone acetonide after Retisert intravitreal implantation in rabbits over a 1-year period. J Ocul Pharmacol Ther 2004;20:269-75
   PubMed Web of Science ®Google Scholar
• MHRA. Public Assessment Report Decentralized procedure. Iluvien 190 micrograms intravitreal implant in injector. 2012. Available from: http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con171936.pdf [Last accessed 10 December 2014]
   Google Scholar
• Campochiaro PA, Hafiz G, Shah SM, et al. Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert. Ophthalmology 2010;117:1393-9; e3
   PubMed Web of Science ®Google Scholar
• Sanford M. Fluocinolone acetonide intravitreal implant (Iluvien(R)): in diabetic macular oedema. Drugs 2013;73:187-93
   PubMed Web of Science ®Google Scholar
• Ayalasomayajula SP, Ashton P, Kompella UB. Fluocinolone inhibits VEGF expression via glucocorticoid receptor in human retinal pigment epithelial (ARPE-19) cells and TNF-alpha-induced angiogenesis in chick chorioallantoic membrane (CAM). J Ocul Pharmacol Ther 2009;25:97-103
   PubMed Web of Science ®Google Scholar
• Campochiaro PA, Brown DM, Pearson A, et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology 2012;119:2125-32
   PubMed Web of Science ®Google Scholar
• Goldstein DA, Godfrey DG, Hall A, et al. Intraocular pressure in patients with uveitis treated with fluocinolone acetonide implants. Arch Ophthalmol 2007;125:1478-85
   PubMed Web of Science ®Google Scholar
• Highlights of precribing information for Iluvien 2014. Alimera Sciences. Available from: http://www.alimerasciences.com/wp-content/uploads/2014/09/iluvien-prescribing-information.pdf [Last accessed 26 January 2015]
   Google Scholar
• Pescosolido N, Campagna O, Barbato A. Diabetic retinopathy and pregnancy. Int Ophthalmol 2014;34(4):989-97
   PubMed Web of Science ®Google Scholar
• Vestgaard M, Ringholm L, Laugesen CS, et al. Pregnancy-induced sight-threatening diabetic retinopathy in women with Type 1 diabetes. Diabet Med 2010;27:431-5
   PubMed Web of Science ®Google Scholar
• Pratt RM, Kim CS, Grove RI. Role of glucocorticoids and epidermal growth factor in normal and abnormal palatal development. Curr Top Dev Biol 1984;19:81-101
   PubMed Web of Science ®Google Scholar
• Piddington R, Herold R, Goldman AS. Further evidence for a role of arachidonic acid in glucocorticoid teratogenic action in the palate. Proc Soc Exp Biol Med 1983;174:336-42
   PubMed Web of Science ®Google Scholar
• Petri M. Immunosuppressive drug use in pregnancy. Autoimmunity 2003;36:51-6
   PubMed Web of Science ®Google Scholar
• Ramsey-Goldman R, Schilling E. Immunosuppressive drug use during pregnancy. Rheum Dis Clin North Am 1997;23:149-67
   PubMed Web of Science ®Google Scholar
• Bleiberg J, Brodkin RH. Therapeutic efficacy of fluocinolone acetonide ointment and cream. Arch Dermatol 1964;89:561
   PubMed Web of Science ®Google Scholar
• Cunha-Vaz J, Ashton P, Iezzi R, et al. Sustained delivery fluocinolone acetonide vitreous implants: long-term benefit in patients with chronic diabetic macular edema. Ophthalmology 2014;121:1892-903
   PubMed Web of Science ®Google Scholar
• Lardenoye CW, Probst K, DeLint PJ, et al. Photoreceptor function in eyes with macular edema. Invest Ophthalmol Vis Sci 2000;41:4048-53
   PubMed Web of Science ®Google Scholar
• Al Dhibi HA, Arevalo JF. Clinical trials on corticosteroids for diabetic macular edema. World J Diabetes 2013;4:295-302
   PubMedGoogle Scholar
• Ozdek S, Deren YT, Gurelik G, et al. Posterior subtenon triamcinolone, intravitreal triamcinolone and grid laser photocoagulation for the treatment of macular edema in branch retinal vein occlusion. Ophthalmic Res 2008;40:26-31
   PubMed Web of Science ®Google Scholar
• Boyer DS, Yoon YH, Belfort RJr, et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology 2014;121:1904-14
   PubMed Web of Science ®Google Scholar
• Messenger WB, Beardsley RM, Flaxel CJ. Fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema. Drug Des Devel Ther 2013;7:425-34
   PubMed Web of Science ®Google Scholar